Lancifodilactone C exhibits potential in anti-cancer research due to its ability to induce apoptosis in tumor cells. It has shown inhibitory effects on the proliferation of certain cancer cell lines, particularly in liver and lung cancers. Its mechanism involves modulation of key signaling pathways such as PI3K/AKT and MAPK, which are critical in cell survival and growth. Additionally, it may enhance the sensitivity of cancer cells to conventional chemotherapeutic agents, suggesting a role as an adjuvant in cancer therapy. Research is ongoing to evaluate its bioavailability and in vivo efficacy.